Table 2 Baseline characteristics of included studies in meta-analysis
Study detail | No. of patients, type | Sex, Male/Female | Median age (years) | Median tumor size (centimeter) | Median follow-up duration (months) |
|---|---|---|---|---|---|
Alam R et al 2018 [14] | PN 231 | 145/86 | 61.3 | 2.4 | |
TA 27 | 13/14 | 71.8 | 2.1 | 36.0 (Total) | |
AS 339 | 190/149 | 70.6 | 1.8 | ||
AS 1978 | NA | NA | 2.8 | > 42.2 | |
Miller BL et al 2018 [15] | PN 31 | NA | Oncocytoma 69.5 chRCC 57.0 | NA | |
TA 14 | NA | NA | 39.9 (Total) | ||
AS 90 | NA | NA | |||
Tang DH et al 2017 [16] | PN 31 | 24/7 | 81.0 | 3.2 | 51.0 (Total) |
AS 31 | 18/13 | 83.0 | 2.7 | ||
Larcher A et al 2015 [17] | TA 553 | 308/245 | 77.0 | 2.7 | 30.0 (Total) |
AS 1307 | 778/529 | 78.0 | 2.8 | ||
Patel HD et al 2015 [18] | PN 1849 | 1070/779 | 65–69 589(31.5%) 70–74 569(27.5%) 75–79 463(25.2%) 80–84 191(19.5%) ≥85 37(8.9%) | < 2 cm 454(41.2%) 2- < 3 cm 776(31.8%) 3- ≤ 4 cm 614 (17.0%) | 56.0 (Total) |
AS 754 | 399/355 | 65–69 589(31.5%) 70–74 569(27.5%) 75–79 463(25.2%) 80–84 191(19.5%) ≥85 37(8.9%) | < 2 cm 134(12.2%) 2- < 3 cm 258(10.6%) 3- ≤ 4 cm 361(10.0%) | ||
Patel N et al 2012 [19] | PN 90 | NA | 58.9 | 2.69 | 33.0 |
AS 71 | 52/19 | 71.9 | 2.2 | 34.0 | |
Lane BR et al 2010 [20] | NSI 286 | 200/86 | 78.0 | 3.0 | 46.8 (Total) |
AS 105 | 58/47 | 81.0 | 2.3 |